ICG-EG8-Sulfo-OSu
Fluorescent Labeling Reagent
-
Product codeI290 ICG-EG8-Sulfo-OSu
-
Chemical name2-[7-[1,1-Dimethyl-3-(4-sulfobutyl)-2H-benzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethyl-3-hexanoylamino-[3,6,9,12,15,18,21,24-octaoxa-26-(3-sulfosuccinimidyl)oxyhexacosanoyl]-1H-benzo[e]indolium, sodium salt
-
MWC68H89N4NaO19S2=1353.57
| Unit size | Price | Item Code |
|---|
Description
Product Description
ICG is a fluorophore, and it has been utilized for over a half-century in human clinical use. Conventional activated ICG dye, ICG-Sulfo-OSu has been utilized in in vivo imaging research as antibody conjugates. However, due to the hydrophobic characteristics which unspecific bound to antibodies are seen (results in higher background). As a next generation of ICG dye, ICG with short PEG linkers such as ICG-PEG4-Sulfo-OSu and ICG-PEG8-SUlfo-OSu are synthesized to increase the hydrophilicity character of the dye. The PEGylated ICGs shows higher covalent binding to antibodies, significantly reducing unspecific binding. Therefore, ICG with short PEG linkers is found to be more suitable compound for in vivo imaging research.
ICG-EG8-Sulfo-OSu [code: I290]
References
<ICG-EG4, EG8 Sulfo-OSu>
1.Sano, K.; Nakajima, T.; Miyazaki, K.; Ohuchi, Y.; Ikegami, T.; Choyke, L. P.; Kobayashi, H.; Bioconjugate Chem., 24, 811-816, (2013).
<ICG-Sulfo-OSu>
1. Ogawa, M.; Kosaka, N.; Choyke, L. P.; Kobayashi, H.; Cancer Res., 69, 1268 – 1272 (2009).
2. Kosaka, N.; Ogawa, M.; Sato, N., Choyke, L.; P.; Kobayashi, H.; J Invest Dermatol, 129, 2818 E822 (2009).
3. Kosaka N.; Ogawa, M.; Choyke, P. L.; Kobayashi H.; Future Oncol., 5, 1501-11 (2009).
4. Nakajima T,; Mitsunaga M,; Bander NH,; Heston WD,; Choyke PL,; Kobayashi H.; Bioconjug Chem., 22,1700-1705 (2011).
5. Ogawa, M.; Regino, C. A.; Seidel, J.; Green, M. V.; Xi, W.; Williams, M.; Kosaka, N.; Choyke, P. L.; Kobayashi, H.; Bioconjug Chem., 20, 2177-84 (2009).
Handling and storage condition
| -20°C, Protect from moisture |
